Traders should monitor the March 9 earnings release and call for actual financial performance, LOQTORZI sales trends, and updates on clinical development. The current lack of data limits immediate trading implications.
CHRS drugs
CHRS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $1.65entry
- T+1 · 9mo ago 0.00%α +0.91% · $1.65
- T+5 · 8mo ago +16.97%α +18.18% · $1.93
- T+20 · 8mo ago −3.03%α +4.91% · $1.60
- T+60 · 6mo ago −0.61%α −9.93% · $1.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Coherus Oncology announced it will release its full-year and fourth-quarter 2025 financial results on March 9, 2026, followed by a conference call. The press release contains no actual financial data, only logistical details for the upcoming earnings announcement.
Key Facts
- Coherus Oncology will release 2025 full-year and Q4 financial results on March 9, 2026, after market close.
- Management will host a conference call at 4:30 p.m. ET on March 9 to discuss results and provide a business update.
- No financial figures or operational updates were disclosed in this announcement.
- The company uses its investor relations website for material disclosures under Regulation FD.
Financial Impact
No financial data disclosed in this release
Risk Factors
- Earnings could miss expectations given the company's small market cap ($250M) and reliance on a single commercial product.
- No forward-looking guidance is provided in this release, increasing uncertainty ahead of the report.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247524 |
Track record
15 reports on CHRS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
- Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
- Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
- Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
- Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
- May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
- May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers